Table 4.
Study and cohort | Serum creatinine | Urine albumin | RBP μg/g creatinine | β2M μg/g creatinine | Fibronectin μg/g creatinine | BBA U/g creatinine | NAG U/g creatinine | |
---|---|---|---|---|---|---|---|---|
Upper reference limit | 1.5 mg/dL | 20 mg/g creatinine | 130 μg/g creatinine | 300 μg/g creatinine | 250 μg/g creatinine | 8.3 U/g creatinine | 5.0 U/g creatinine | |
Franchini et al. [13] | Cobalt-exposed workers, n = 26 | 4.45 mg/g creatinine | 42.1 μg/g creatinine | 120.8 μg/g creatinine | 2.44 U/g creatinine | |||
Control workers, n = 35 | 4.01 mg/g creatinine | 45.8 μg/g creatinine | 85.8 μg/g creatinine | 2.64 U/g creatinine | ||||
Voskaridou et al. [31] | Hbs/β-Thal patients, n = 87 | 0.8 | 454.5 mg/24 h proteinuria | 6.6 U/day | ||||
Controls, n = 30 | 0.7 | 57.4 mg/24 h proteinuria | 2.0 U/day | |||||
Mutti et al. [21] | Normal subjects, n = 300 | 5.1 mg/g creatinine | 38.1 μg/g creatinine | 98 μg/g creatinine | 3.5 U/g creatinine | 57.2 mmol/g creatinine | ||
Idasiak-Piechocka et al. [16] | Chronic glomerulonephritis patients, n = 55 | 245.0 ng/mmol creatinine | ||||||
Healthy subjects, n = 19 | 100.7 ng/mmol creatinine | |||||||
Present study | Patients with MOM, n = 31 | 1.1 mg/dL | 10.4 mg/g creatinine | 49.9 μg/g creatinine | 112.0 μg/g creatinine | 154.6 μg/g creatinine | 1.5 U/g creatinine | 1.7 U/g creatinine |
Controls, n = 30 | 5.2 mg/g creatinine | 50.1 μg/g creatinine | 98 μg/g creatinine | 183 μg/g creatinine | 3.3 U/g creatinine | 3.2 U/g creatinine |
RBP = retinol binding protein; β2M = beta 2 microglobulin; BBA = Brush Border antigen; NAG = N-acetyl-β-D-glucosaminidase; MOM = metal-on-metal.